News about Global Pharma

Granules India Gets ANDA Approval for Trazodone Tablets

Granules now has 65 ANDA approvals from the US FDA (64 final approvals and 1 tentative approval). The current annual US market for Trazodone tablets is approximately USD 128 Million.

Global Pharma | 12/08/2024 | By Aishwarya |  806

Samsung Biologics Joins Pharmaceutical Supply Chain Initiative as Supplier Partner

Samsung Biologics, a global contract development and manufacturing organization (CDMO), has joined the Pharmaceutical Supply Chain Initiative (PSCI) as a Supplier Partner.

Global Pharma | 08/08/2024 | By Aishwarya |  668

Valeo Pharma Announces Appointment of New CEO

Valeo Pharma Inc. has announced that the company’s Chief Development Officer, Al Moghaddam, has been appointed to succeed retiring CEO Steve Saviuk.

Global Pharma | 07/08/2024 | By Aishwarya |  1203

Gland Pharma Reports 16 Percent YoY Revenue Growth in Q1FY25

Gland Pharma has revealed its financial results for the first quarter of FY25, ending June 30, 2024.

Global Pharma | 07/08/2024 | By Aishwarya |  638

Antengene Gets Malaysian Regulatory Agency Approval for XPOVIO Commercialization

Antengene has announced that Malaysian National Pharmaceutical Regulatory Agency has approved a New Drug Application (NDA) for XPOVIO (selinexor).

Global Pharma | 06/08/2024 | By Aishwarya |  612

Skanray Partners with Tata Elxsi to Power Surgical Imaging Technology

Skanray has selected Tata Elxsi as a strategic partner for advanced surgical imaging core technology and software platform development.

Global Pharma | 05/08/2024 | By Aishwarya |  712

ASPA Delivers Keynote at ASIA Security Conference and Exhibition

The Authentication Solution Providers’ Association (ASPA) has announced that Puneet Maithani, Associate Director of Industry Affairs has delivered a compelling keynote address titled ‘ASPA: Leading the Fight Against Counterfeiting and Ensuring Product Authenticity’ at the ASIA Security Conference & Exhibition.

Global Pharma | 05/08/2024 | By Aishwarya |  994

Anivive Bags NIAID Contract Worth Up to USD 33 Million to Progress Valley Fever Vaccine

Anivive Lifesciences Inc. has announced that the National Institute of Allergy and Infectious Diseases (NIAID) has awarded Anivive a new contract worth up to USD 33 million to support the development of a vaccine against the fungus Coccidioides, which causes Valley Fever.

Global Pharma | 03/08/2024 | By Aishwarya |  783

Merck Acquires Mirus Bio to Advance Viral Vector Bioprocessing

Merck has completed the acquisition of Mirus Bio for approximately USD 600 million (around EUR 550 million), following regulatory clearances and the fulfillment of other customary closing conditions.

Global Pharma | 03/08/2024 | By Aishwarya |  700

AbbVie Completes Acquisition of Cerevel Therapeutics

AbbVie has announced the completion of its acquisition of Cerevel Therapeutics.

Global Pharma | 02/08/2024 | By Aishwarya |  630